Resolute® and Xience V® polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 7, 2013, Pages

  Van Dyck, Christophe J ^a,b   Hoymans, Vicky Y ^a,b   Bult, Hidde ^b   Fransen, Erik ^b   Haine, Steven ^a,b   Bosmans, Johan M ^a,b   Timmermans, Jean Pierre ^b   Vrints, Christiaan J ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

animal model; atherosclerosis; drug eluting stents; resolute; Xience V

Indexed keywords

EVEROLIMUS; POLYMER; UNCLASSIFIED DRUG; XIENCE V EES; ZOTAROLIMUS; CARDIOVASCULAR AGENT; RAPAMYCIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BALLOON CATHETER; BARE METAL STENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELUTING STENT; INFLAMMATION; MALE; NEOINTIMA; NONHUMAN; TISSUE GROWTH; VASCULAR ENDOTHELIUM; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; ENDOTHELIUM CELL; ILIAC ARTERY; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROSTHESIS; RABBIT; RADIOGRAPHY; TIME; ULTRASTRUCTURE; VASCULAR SYSTEM INJURIES; BLOOD VESSEL INJURY; EQUIPMENT; INJURY;

ANGIOPLASTY, BALLOON; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; ILIAC ARTERY; INFLAMMATION; MALE; NEOINTIMA; PROSTHESIS DESIGN; RABBITS; SIROLIMUS; TIME FACTORS; VASCULAR SYSTEM INJURIES;

EID: 84878252317     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24595     Document Type: Article

References (35)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R,; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS,. A paclitaxel-eluting stent for the prevention of coronary stenosis. N Engl J Med 2003; 348: 1537-1545.
3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pcock SJ, Mehran R, Leon MB,. Safety and efficacy of sirolimus- and paclitaxel- eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
4. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S,. Incidence and correlates of drug- eluting stent thrombosis in routine clinical practice. J Am Coll Cardiol 2008; 52: 1134-1140.
5. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C,; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
6. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S,. Incomplete neointima coverage of sirolimus eluting stents: Angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
7. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Lida O, Sera F, Nanto S, Hori M, Nagata S,. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: Comparison with bare metal stents. Circulation 2007; 116: 910-916.
8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
9. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, tefera K, Skorija K, Weber DK, Gold HK, Virmani R,. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
10. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C,. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth after six months. J Am Coll Cardiol 2000; 36: 2325-2332.
11. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE,. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
12. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P,. Outcomes associated with drug-eluting and bare metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
13. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A,. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
14. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R,. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44M.
15. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342.
16. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R,. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011; 4: 38-46.
17. Schwartz RS, Chronos NA, Virmani R,. Preclinical restenosis models and drug-eluting stents. Still important, still much to learn. J Am Coll Cardiol 2004; 44: 1373-1385.
18. Suzuki Y, Yeung AC, Ikeno F,. The preclinical animal model in the translational research of interventional cardiology. J Am Coll Cardiol Interv 2009; 2: 373-383.
19. Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, Wong J, Wilcox J,. The next generation Endeavor Resolute stent: Role of the Biolinx polymer system. Eurointervention 2007; 3: 137-139.
20. Stary HC,. Composition and classification of human atherosclerotic lesions. Virchows Archiv A Pathol Anat 1992; 421: 277-2920.
21. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R,. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
22. Nakazawa G, Finn AV, Virmani R,. Vascular pathology of drug-eluting stents. Herz 2007; 32: 274-280.
23. Kockx MM, De Meyer GR, Andries LJ, Bult H, Jacob WA, Herman AG,. The endothelium during cuff-induced neointima formation in the rabbit carotid artery. Arterioscler Thromb 1993; 13: 1874-1884.
24. Bosmans JM, Kockx MM, Vrints CJ, Bult H, De Meyer GR, Herman AG,. Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery. Arterioscler Thromb Vasc Biol 1997; 17: 634-645.
25. De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, Bult H,. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19: 2524-2534.
26. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ, for the RESOLUTE Investigators. Clinical and angiographic results with the next-generation Resolute stent system. A prospective, multicenter, first-in-human trial. J Am Coll Cardiol Interv 2009; 2: 977-985.
27. Mauri L, Leon MB, Yeung AC, Negoita M, Keyes J, Massaro JM,. Rationale and design of the clinical evaluation of the Resolute Zotarolimus-eluting stent system in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). Am Heart J 2011; 161: 807-814.
28. Yeung A, Leon M, Jain A, Tolleson T, Spriggs D, Mc Laurin B, Pompa J, Fitzgerald P, Cutlip D, Massaro J, Mauri L,. Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries. J Am Coll Cardiol 2011; 57: 1778-1783.
29. Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K,. Recent progress in percutaneous coronary intervention: Evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis 2010; 21: 46-56.
30. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G,. Next generation drug- eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008; 4: 31-38.
31. Beijk MA, Piek JJ,. Xience V everolimus-eluting coronary stent system: A novel second generation drug-eluting stent. Expert Rev Med Devices 2007; 4: 11-21.
32. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S,. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 123-135.
33. Stefanini GG, Serruys PW, Silber S, Khattab AA, Van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S,. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularisation with zotarolimus- and everolimus-eluting stents. J Am Coll Cardiol 2011; 57: 2221-2232.
34. Silber S, Windecker S, Vranckx P, Serruys PW, on behalf of the RESOLUTE All Corners investigators. Unrestricted randomized use of two new generation drug-eluting coronary stents: 2-year patient- related versus stent-related outcomes from the RESOLUTE All Corners trial. Lancet 2011; 377: 1241-1247.
35. Virmani R, Kolodgie FD, Farb A, Lafont A,. Drug eluting stents: Are human and animal studies comparable? Heart 2003; 89: 133-138.